Literature DB >> 28510455

Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine.

Henrike Bruckmueller1, Paul Martin1, Meike Kähler1, Sierk Haenisch1, Marek Ostrowski2, Marek Drozdzik3, Werner Siegmund4, Ingolf Cascorbi1, Stefan Oswald4.   

Abstract

Intestinal drug transporters are crucial determinants for absorption and oral bioavailability of drugs. In healthy tissue donors, a recent study revealed profound discrepancies between mRNA expression and protein abundance as well as differences in the protein content between small and large intestine for clinically relevant multidrug transporters as the ATP binding cassette transporter subfamily B member 1 (ABCB1) and subfamily C member 3 (ABCC3) and the solute carrier family 15 member 1 (SLC15A1, PEPT1). As the mechanisms underlying these observations remained unclear, the aim of the present study was to elucidate the intestinal regiospecific microRNA profile under physiological conditions and identify specific microRNAs contributing to the post-transcriptional regulation of major drug transporters. For this purpose, tissue samples were collected from six intestinal sites obtained from six healthy tissue donors. The expression of 754 microRNAs was determined using qRT-PCR based low density arrays, and microRNA expression levels were correlated with transporter protein abundance quantified by targeted proteomics. A total of 241 microRNA-transporter pairs were identified, showing significant negative correlations to protein abundance (p < 0.05). Out of these, for nine pairs, the binding of the microRNA to the respective transporter 3'-UTR was predicted in silico. Besides the already known interactions of miR-27a-3p-ABCB1 and miR-193a-3p-PEPT1, reporter gene assays confirmed binding of miR-192-5p to the ABCC3 3'-UTR (reduction of reporter gene activity by 31%; p = 0.0012), miR-409-3p to the ABCB1 3'-UTR (reduction by 38%; p = 0.0006), and miR-193b-3p as well as miR-27a-3p to PEPT1 3'-UTR (reduction by 49% (p = 0.0012) and 20% (p = 0.0043), respectively). These results suggest that mucosal microRNA expression contributes to the explanation of discrepancies between mRNA expression and protein abundance as well as site-dependent differences in protein content along the human intestine under physiological conditions, as exemplified for ABCB1, ABCC3, and PEPT1.

Entities:  

Keywords:  drug transporter; gene regulation; intestine; microRNA; protein abundance

Mesh:

Substances:

Year:  2017        PMID: 28510455     DOI: 10.1021/acs.molpharmaceut.7b00076

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  10 in total

1.  Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.

Authors:  Roberto H Barbier; Edel M McCrea; Kristi Y Lee; Jonathan D Strope; Emily N Risdon; Douglas K Price; Cindy H Chau; William D Figg
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.996

Review 2.  Overview of Drug Transporters in Human Placenta.

Authors:  Michiko Yamashita; Udo R Markert
Journal:  Int J Mol Sci       Date:  2021-12-05       Impact factor: 5.923

Review 3.  Regulation of Drug Transport Proteins-From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium.

Authors:  Kim L R Brouwer; Raymond Evers; Elizabeth Hayden; Shuiying Hu; Cindy Yanfei Li; Henriette E Meyer Zu Schwabedissen; Sibylle Neuhoff; Stefan Oswald; Micheline Piquette-Miller; Chitra Saran; Noora Sjöstedt; Jason A Sprowl; Simone H Stahl; Wei Yue
Journal:  Clin Pharmacol Ther       Date:  2022-05-24       Impact factor: 6.903

Review 4.  Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta.

Authors:  Valerio Taggi; Mario Riera Romo; Micheline Piquette-Miller; Henriette E Meyer Zu Schwabedissen; Sibylle Neuhoff
Journal:  Pharmaceutics       Date:  2022-06-29       Impact factor: 6.525

5.  MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells.

Authors:  Meike Kaehler; Johanna Ruemenapp; Daniel Gonnermann; Inga Nagel; Oliver Bruhn; Sierk Haenisch; Ole Ammerpohl; Daniela Wesch; Ingolf Cascorbi; Henrike Bruckmueller
Journal:  Oncotarget       Date:  2017-09-26

6.  Membrane Transporters in Human Parotid Gland-Targeted Proteomics Approach.

Authors:  Joanna Lapczuk-Romanska; Diana Busch; Ewa Gieruszczak; Agnieszka Drozdzik; Katarzyna Piotrowska; Robert Kowalczyk; Stefan Oswald; Marek Drozdzik
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

Review 7.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.

Authors:  Mohamed Elmeliegy; Manoli Vourvahis; Cen Guo; Diane D Wang
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

8.  Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine.

Authors:  Narciso Couto; Zubida M Al-Majdoub; Stephanie Gibson; Pamela J Davies; Brahim Achour; Matthew D Harwood; Gordon Carlson; Jill Barber; Amin Rostami-Hodjegan; Geoffrey Warhurst
Journal:  Drug Metab Dispos       Date:  2020-01-20       Impact factor: 3.922

9.  Monocarboxylate Transporter 1 (MCT1) in Liver Pathology.

Authors:  Marek Droździk; Sylwia Szeląg-Pieniek; Justyna Grzegółkowska; Joanna Łapczuk-Romańska; Mariola Post; Pawel Domagała; Janusz Miętkiewski; Stefan Oswald; Mateusz Kurzawski
Journal:  Int J Mol Sci       Date:  2020-02-26       Impact factor: 5.923

10.  A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity.

Authors:  Samir H Barghout; Ahmed Aman; Kazem Nouri; Zachary Blatman; Karen Arevalo; Geethu E Thomas; Neil MacLean; Rose Hurren; Troy Ketela; Mehakpreet Saini; Moustafa Abohawya; Taira Kiyota; Rima Al-Awar; Aaron D Schimmer
Journal:  JCI Insight       Date:  2021-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.